Evidence map›Paper›PMID 34249319›Full record

SynthesisFrontline gastroenterology2021

Gastrointestinal manifestations of COVID-19 in children: a systematic review and meta-analysis.

Anthony K Akobeng, Ciaran Grafton-Clarke, Ibtihal Abdelgadir, Erica Twum-Barimah, Morris Gordon

Abstract readSystematic Review
In one paragraph

Synthesis in Frontline gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Paediatrics & child health · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. COVID-19 in a group of children with asthma: presentation, severity, and outcome.American journal of clinical and experimental immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anthony K AkobengDivision of Gastroenterology, Hepatology, and Nutrition, Sidra Medicine, Doha, Qatar.ORCID 0000-0001-5418-3728
Ciaran Grafton-ClarkeUniversity of Leicester, Leicester, Leicestershire, UK.ORCID 0000-0002-8537-0806
Ibtihal AbdelgadirWeill Cornell Medicine, Doha, Qatar.
Erica Twum-BarimahPaediatrics, Milton Keynes University Hospital, Milton Keynes, Milton Keynes, UK.
Morris GordonUniversity of Central Lancashire, Preston, Lancashire, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo summarise the published evidence on the gastrointestinal manifestations of COVID-19 in children and to determine the prevalence of gastrointestinal symptoms.

methodsIn this systematic review and meta-analysis, we searched PubMed, Embase, CINAHL and the WHO's database of publications on novel coronavirus. We included English language studies that had described original demographic and clinical characteristics of children diagnosed with COVID-19 and reported on the presence or absence of gastrointestinal symptoms. Meta-analysis was conducted using the random-effects model. The pooled prevalence of gastrointestinal symptoms was expressed as proportion and 95% CI.

resultsThe search identified 269 citations. Thirteen studies (nine case series and four case reports) comprising data for 284 patients were included. Overall, we rated four studies as having a low risk of bias, eight studies as moderate and one study as high risk of bias. In a meta-analysis of nine studies, comprising 280 patients, the pooled prevalence of all gastrointestinal symptoms was 22.8% (95% CI 13.1% to 35.2%; I

conclusionsNearly a quarter of children with COVID-19 have gastrointestinal symptoms. It is important for clinicians to be aware of the gastrointestinal manifestation of COVID-19. PROSPERO REGISTRATION NUMBER: CRD42020177569.

Indexed as

abdominal paindiarrhoeainfectious disease

Identifiers

PMID34249319
PMCPMC8231431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.